Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock

Investors who take an interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) should definitely note that the Chief Financial Officer, Jason Haas, recently paid US$1.61 per share to buy US$161k worth of the stock. That certainly has us anticipating the best, especially since they thusly increased their own holding by 407%, potentially signalling some real optimism.

Check out our latest analysis for Syros Pharmaceuticals

Syros Pharmaceuticals Insider Transactions Over The Last Year

In fact, the recent purchase by Jason Haas was the biggest purchase of Syros Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. Even though the purchase was made at a significantly lower price than the recent price (US$1.95), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

In the last twelve months Syros Pharmaceuticals insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

Syros Pharmaceuticals is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Syros Pharmaceuticals Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Our data suggests Syros Pharmaceuticals insiders own 1.5% of the company, worth about US$633k. We consider this fairly low insider ownership.

So What Does This Data Suggest About Syros Pharmaceuticals Insiders?

It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Syros Pharmaceuticals stock. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 7 warning signs for Syros Pharmaceuticals (of which 3 don't sit too well with us!) you should know about.

But note: Syros Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.